基于T细胞表位的结核亚单位疫苗候选的构建与免疫原性
研究克隆结核分枝杆菌38-kDa抗原(PstS1)及其T细胞表位片段PstS1p,在小鼠中评估免疫应答。PstS1和PstS1p均诱导显著抗原特异性IgG、Th1型反应和CD4+ T细胞增殖,且PstS1p细胞免疫更强。提示PstS1p具高免疫原性,可能为有前景的结核候选疫苗。
要点
- PstS1与PstS1p均增强小鼠抗原特异性IgG抗体应答。
- 两者均诱导Th1型反应并促进CD4+ T细胞增殖。
- PstS1p较PstS1诱导更强的细胞免疫应答。
核心结论
- PstS1p在小鼠中具高免疫原性,可能是控制结核的有前景候选疫苗。
研究设计与样本
- 克隆结核分枝杆菌38-kDa抗原PstS1及其T细胞表位片段PstS1p,原核表达后在小鼠中评估免疫与免疫原性。
主要发现
- PstS1和PstS1p均显著提高小鼠血清抗原特异性IgG抗体。
- 两者均诱导Th1型反应并促进CD4+ T细胞增殖。
- 与PstS1相比,PstS1p促进更强的细胞介导免疫应答。
- 两种重组蛋白原核表达时主要以包涵体形式存在。
临床怎么用
- 为结核疫苗研发提供候选抗原,PstS1p值得进一步临床前评价。
局限性
- 原文未报告样本量、统计阈值及人体数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite antibiotic treatment and Bacille Calmette-Guérin (BCG) vaccination, Mycobacterium tuberculosis remains a major public health burden in most developing countries. Therefore, developing an improved vaccine is high priority. In this study, we cloned the genes of the immunodominant antigen of M. tuberculosis viz. its 38-kDa antigen (Pst homolog) (Rv0934, PstS1), and its T cell epitopes (amino acid [aa]169-405 and [aa]802-1119), which we termed PstS1p. Prokaryotic expression showed that the two recombinant proteins were mainly in the form of inclusion bodies. We also evaluated the immunity and immunogenicity of PstS1 and PstS1p. Both PstS1 and its T cell epitopes elicited significantly higher antigen-specific immunoglobulin G (IgG) antibodies in mouse serum, indicating that they enhanced antibody response. They also elicited the T helper 1 (Th1)-type response and promoted CD4+ T cell proliferation. Compared to PstS1, PstS1p promoted stronger cell-mediated immune response. These data indicate that PstS1p is highly immunogenic in mice, and may be a promising candidate vaccine for controlling tuberculosis.
引用
- Fan X, Li X, Wan K, et al. Construction and immunogenicity of a T cell epitope-based subunit vaccine candidate against Mycobacterium tuberculosis. Vaccine. 2021. PMID: 34702619. doi:10.1016/j.vaccine.2021.10.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。